mTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation
What this study shows
Explained HOW rapamycin calms 'inflammaging'. Senescent cells spew inflammatory signals (the SASP) that damage surrounding tissue and even feed tumors. mTOR powers this by translating IL1A, the cytokine at the top of the cascade. Rapamycin selectively shuts it down - and blocked senescent cells from fueling prostate tumor growth in mice.
At a glance
| Evidence type | M Molecular — cells, biochemistry, structure Marked M because it is molecular or in-vitro work (model: Human cells + mouse xenografts) rather than a whole-organism health-outcome study. That is often exactly where causal biology gets established -- the code says which system the finding was shown in, and nothing about how good the work is. |
| Study type | 5 - Mechanistic / In Vitro |
| Model system | Human cells + mouse xenografts |
| Journal | Nature Cell Biology |
| Year | 2015 |
| Peer reviewed | Yes |
| Record last updated | 2026-10-01 |
| Source | DOI 10.1038/ncb3195 · PMID 26147250 · Free full text (PMC4691706) |
Extracted findings
These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.
| Intervention | Rapamycin (mTORC1 inhibition) |
| Target | mTORC1 / IL1A / SASP |
| Model | Human cells + mouse xenografts |
| Effect | Rapamycin blunts the pro-tumorigenic senescence-associated secretory phenotype by suppressing IL1A translation |
In the Atlas
Related topics
Links in the pathway map
Open questions that cite this study
- Cited as supporting evidence for the open question How much of rapamycin's healthspan benefit runs through fewer senescent cells?.
More studies on this topic
- Impaired Chaperone-Mediated Autophagy Accelerates Intervertebral Disc Degeneration by Inducing MIDN Accumulation to Target TSC2 for Proteasomal Degradation (2026)
- Spatial coupling of mTOR and autophagy augments secretory phenotypes (2011)
- Therapeutic reversal of cellular senescence: A systematic review of senolytics, senomorphics and anti-ageing therapies in human clinical trials (2026)
- Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2-independent mechanism (2017)
Was this page useful?
Thank you. Your answer was counted anonymously.